Clinical trials: Left Ventricle Function
Renal Dialysis, Hemodiafiltration
Effect of Intradialytic Exercise on Left Ventricular Diastolic Function in Hemodialysis Patients
Introduction: Cardiovascular disease is the leading cause of morbidity and mortality in patients undergoing hemodialysis, largely due to structural cardiac changes associated with left ventricular diastolic dysfunction.
- Conditions
- Renal Dialysis, Hemodiafiltration, Diastolic Dysfunction, Kidney Failure
- Trial name
- EXE-HDF (NCT06584734)
- Testing
- Not exercise, Exercise during hemodiafiltration session
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Permanent Atrial Fibrillation
Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)
Atrial fibrillation is a common heart rhythm disturbance, causing important discomfort for patients, a high risk of stroke, frequent hospital admissions and a two-fold increase in death.
- Trial name
- RATE-AF (NCT02391337)
- Testing
- Bisoprolol, Digoxin
- Where
- 2 sites in United Kingdom
- Volunteers
- 161 people
- Sponsor
- University of Birmingham
Heart Diseases, Left Ventricular Dysfunction
InterventiOn of Biventricular Pacemaker Function on ventrIcular Function Among Patients With LVAD's
The primary reason the investigators are doing this study are to understand how the right side of the heart functions in heart failure patients with left ventricular assist devices (LVADs, or "mechanical hearts").
- Trial name
- ROBIN (NCT03232736)
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Left Ventricular Dysfunction
PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing
This study will be done in patients who require the implantation of a cardiac pacemaker (an electronic device that controls the heartbeat) for complete heart block (a heart rhythm abnormality resulting in a slow heart beat).
- Trial name
- PROTECT-PACE (NCT00461734)
- Testing
- RV lead placement site
- Where
- 18 sites in Australia, New Zealand and 1 more
- Volunteers
- 248 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Diastolic Dysfunction, Left Ventricular Hypertrophy
Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy
This is a clinical, randomised, double-blinded study in which patients eligible for aortic valve replacement are enrolled. Patients receive infusion of either levosimendan or placebo 4 hours prior to surgery and until the end of…
- Trial name
- NCT01188369
- Testing
- levosimendan
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- University of Aarhus
Congestive Heart Failure
Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
In congestive heart failure, cardiac output is low, blood pressure is high, and the body becomes congested with fluid. In normal people, when there is high blood pressure, the heart muscle cells secrete a hormone that excretes…
- Trial name
- PPG1 (NCT00387621)
- Testing
- Nesiritide, Saline
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Horng Chen
Heart Failure, Left Ventricular Dysfunction
Effects of Viagra on Heart Function in Patients With Heart Failure
Sildenafil (Viagra) is known to reduce pulmonary hypertension. Heart failure patients also have pulmonary hypertension and several recent reports have shown that sildenafil leads to an improvement in their exercise capacity.
- Trial name
- NCT00781508
- Testing
- sildenafil
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- MetroHealth Medical Center
Left Ventricle Function
Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction
To explore if AZD1305 compromises left ventricular performance in patients with left ventricular dysfunction
- Trial name
- NCT00748982
- Testing
- AZD1305
- Where
- Sweden
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Aortic Valve Stenosis
Hemodynamic Comparison of Tissue Aortic Valves
The purpose of this study is to: 1. Assess for hemodynamic differences at rest and with exercise between three clinically available tissue aortic valves. 2.
- Trial name
- NCT01635244
- Testing
- Aortic valve replacement
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Michigan
Amyloidosis
Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698
The study is intended to evaluate whether monthly repeated courses of administration of GSK2315698 followed by GSK2398852 is associated with a reduction in cardiac amyloid load in patients with cardiac amyloidosis, monitored by…
- Trial name
- NCT03044353
- Testing
- GSK2315698 (CPHPC), GSK2398852 (anti-SAP mAb)
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 7 people
- Sponsor
- GlaxoSmithKline
Heart Failure, Cardiomyopathy
The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in Patients Undergoing LVAD Implantation
The main purpose of this research is to determine whether injecting mesenchymal precursor cells (MPC) into the heart during surgery to implant a left ventricular assist device (LVAD) is safe.
- Conditions
- Heart Failure, Cardiomyopathy, Ventricular Dysfunction
- Trial name
- NCT01442129
- Testing
- MPC Intramyocardial injection, Control Solution
- Where
- 11 sites in United States
- Volunteers
- 30 people
- Sponsor
- Deborah Ascheim
Myocardial Infarction, Iron-deficiency
An Open Study on the Efficacy of Iron Therapy Using iv Iron Relative to Oral Iron for Increasing LV Systolic Function
The OPERA-MI trial evaluates the effect of i.v. ferric carboxymaltose compared to the effect of oral iron, on left ventricular systolic function.
- Trial name
- OPERA-MI (NCT05309499)
- Testing
- ferric carboxymaltose, ferrous sulphate
- Where
- Russia
- Volunteers
- 298 people
- Sponsor
- Kazan State Medical University
Mitral Regurgitation
Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)
The investigators hypothesize that beta-1 receptor blockade (ß1-RB) attenuates extracellular matrix (ECM) degradation and progressive adverse Left Ventricular (LV) remodeling and failure in the volume overload of mitral…
- Trial name
- P1A1 (NCT01052428)
- Testing
- metoprolol succinate (Toprol XL)
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Refractory Angina
Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina
Therapeutic neovascularization is an innovative strategy for cardiac tissue recovery due to chronic, intense ischemia. Thus stem cell therapy has become a promising procedure for the large number of patients with refractory…
- Trial name
- ReACT (NCT01966042)
- Testing
- Local sedation, Bone Marrow Aspiration, Minithoracotomy
- Where
- Brazil
- Volunteers
- 13 people
- Sponsor
- CellPraxis Bioengenharia Ltda.
Obesity, Diabetes
Metabolic Parameters 3 Months, 9 Months, and 2 Years After Bariatric Surgery
An original cohort of 43 patients were recruited for analysis of anthropometrics, metabolic profile, skeletal muscle biopsy, echocardiogram at baseline, 3 months and 9 months post bariatric surgery.
- Conditions
- Obesity, Diabetes, Heart Failure, Insulin Resistance
- Trial name
- NCT00178633
- Testing
- Bariatric surgery
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- The University of Texas Health Science Center, Houston
Post MI Left Ventricular Dysfunction
IdeNtifying High riSk Patients Post Myocardial Infarction With REduced Left Ventricular Function Using External Loop Recorders (INSPIRE-ELR Study)
The purpose of the INSPIRE-ELR study is to characterize arrhythmias in post MI low EF (≤35%) patients in the acute phase (at discharge from hospital after index MI) and chronic phase (at 8-10 weeks after index MI) and to…
- Trial name
- INSPIRE-ELR (NCT01995552)
- Testing
- External Loop Recorder
- Where
- India
- Volunteers
- 250 people
- Sponsor
- Medtronic BRC
HER2 Positive Breast Cancer, Left Ventricular Function Systolic Dysfunction
Cardiac Safety Study in Patients With HER2 + Breast Cancer
HER2 positive breast cancer cells have more HER2 receptor (a protein on the surface of cells) than normal breast cells. Approximately 30% of patients with breast cancer have HER2 positive breast cancer.
- Trial name
- SAFE-HEaRt (NCT01904903)
- Testing
- Trastuzumab, Pertuzumab, Ado Trastuzumab Emtansine
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Medstar Health Research Institute
Hypertension
Irbesartan and Atenolol in Hypertensive Heart Disease
The renin-angiotensin-aldosterone system has been implicated in the control of structural changes of the heart and the vasculature, beyond the effects on blood pressure.
- Trial name
- SILVHIA (NCT00389168)
- Testing
- Irbesartan, Atenolol
- Where
- Sweden
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Ischemic Cardiomyopathy
Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure
This is a phase II, randomized, placebo-controlled clinical trial designed to assess feasibility, safety, and effect of autologous bone marrow-derived mesenchymal stem cells (MSCs) and c-kit+ cells both alone and in combination…
- Trial name
- CONCERT-HF (NCT02501811)
- Testing
- Mesenchymal Stem Cells (MSC), c-kit+ cells
- Where
- 7 sites in United States
- Volunteers
- 125 people
- Sponsor
- The University of Texas Health Science Center, Houston
Chronic Heart Failure
Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure
This was a multicenter, randomized, double-blind, crossover, placebo-controlled, Phase II clinical study that evaluated the effect of serelaxin versus placebo (both in addition to SoC) on the release of hs-cTnI, in patients with…
- Trial name
- RELAX-Cardio (NCT02625922)
- Testing
- Serelaxin
- Where
- 9 sites in Germany, Switzerland and 1 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals